ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas.
San Antonio, United States. In Clin Cancer Res, 2004
PURPOSE: To determine the feasibility of administration, safety, toxicity, immunogenicity, pharmacokinetics, maximum tolerated dose, and biodistribution of ING-1, a high-affinity, Human-Engineered monoclonal antibody (heMAb) to the Mr 40,000 epithelial cell adhesion molecule Ep-CAM, in patients with advanced adenocarcinomas.
Technology evaluation: ING-1, XOMA.
United States. In Curr Opin Mol Ther, 2003
XOMA is developing ING-1, a human engineered immunoglobulin G1 antibody, as a potential treatment for carcinoma and solid tumors.
Immunological effects of levamisole in vitro.
Madison, United States. In J Immunother (1991), 1991
No significant enhancement in the expression of three tumor-associated antigens (880364, NRCO-4, and ING-1) and the intercellular adhesion molecule-1 (ICAM-1) antigen on four human cancer cell lines was observed following in vitro exposure to levamisole.